Heart transplantation immunosuppressive therapy: Difference between revisions
Jump to navigation
Jump to search
Ifrah Fatima (talk | contribs) |
Ifrah Fatima (talk | contribs) |
||
| Line 6: | Line 6: | ||
==Immunosuppressive Therapy== | ==Immunosuppressive Therapy== | ||
Post-transplantation immunosuppressive therapy consists of two stages- Induction and | Post-transplantation immunosuppressive therapy consists of two stages- | ||
* Induction- Intense therapy for the first 2-3 months to prevent acute graft rejection | |||
* Maintenance- Throughout the life of the patient to combat both acute and chronic rejevtion. <ref name="ChambersYusen2017">{{cite journal|last1=Chambers|first1=Daniel C.|last2=Yusen|first2=Roger D.|last3=Cherikh|first3=Wida S.|last4=Goldfarb|first4=Samuel B.|last5=Kucheryavaya|first5=Anna Y.|last6=Khusch|first6=Kiran|last7=Levvey|first7=Bronwyn J.|last8=Lund|first8=Lars H.|last9=Meiser|first9=Bruno|last10=Rossano|first10=Joseph W.|last11=Stehlik|first11=Josef|title=The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report—2017; Focus Theme: Allograft ischemic time|journal=The Journal of Heart and Lung Transplantation|volume=36|issue=10|year=2017|pages=1047–1059|issn=10532498|doi=10.1016/j.healun.2017.07.016}}</ref> | |||
Even though regimens vary from center to center and case to case, most regimens consist of 2-3 drugs, usually including- <ref>{{cite journal|doi=10.1016/j.healun.2017.07.019.}}</ref> <ref name="SöderlundRådegran2015">{{cite journal|last1=Söderlund|first1=Carl|last2=Rådegran|first2=Göran|title=Immunosuppressive therapies after heart transplantation — The balance between under- and over-immunosuppression|journal=Transplantation Reviews|volume=29|issue=3|year=2015|pages=181–189|issn=0955470X|doi=10.1016/j.trre.2015.02.005}}</ref> | Even though regimens vary from center to center and case to case, most regimens consist of 2-3 drugs, usually including- <ref>{{cite journal|doi=10.1016/j.healun.2017.07.019.}}</ref> <ref name="SöderlundRådegran2015">{{cite journal|last1=Söderlund|first1=Carl|last2=Rådegran|first2=Göran|title=Immunosuppressive therapies after heart transplantation — The balance between under- and over-immunosuppression|journal=Transplantation Reviews|volume=29|issue=3|year=2015|pages=181–189|issn=0955470X|doi=10.1016/j.trre.2015.02.005}}</ref> | ||
Revision as of 13:14, 7 June 2020
|
Heart transplantation Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Heart transplantation immunosuppressive therapy On the Web |
|
American Roentgen Ray Society Images of Heart transplantation immunosuppressive therapy |
|
Risk calculators and risk factors for Heart transplantation immunosuppressive therapy |
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D.; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [1]
Immunosuppressive Therapy
Post-transplantation immunosuppressive therapy consists of two stages-
- Induction- Intense therapy for the first 2-3 months to prevent acute graft rejection
- Maintenance- Throughout the life of the patient to combat both acute and chronic rejevtion. [1]
Even though regimens vary from center to center and case to case, most regimens consist of 2-3 drugs, usually including- [2] [3]
- Calcineurin inhibitor- Tacrolimus or Cyclosporin; known to cause nephrotoxicity
- Anti-metabolite- Mycophenolate mofetil, Azathioprine
- Glucocorticoids- tapering dose
- Mammalian target of rapamycin [m-TOR] inhibitors and other strategies are aimed at minimizing the use of calcineurin inhibitors and corticosteroids.[4]
- Proliferation signal inhibitors (sirolimus and everolimus)- In the case of cardiac allograft vasculopathy (CAV) or renal insufficiency
- Monoclonal Antibody OKT3- Associated with an increase in the incidence of post-transplantation lymphoproliferative disorder[5]
References
- ↑ Chambers, Daniel C.; Yusen, Roger D.; Cherikh, Wida S.; Goldfarb, Samuel B.; Kucheryavaya, Anna Y.; Khusch, Kiran; Levvey, Bronwyn J.; Lund, Lars H.; Meiser, Bruno; Rossano, Joseph W.; Stehlik, Josef (2017). "The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report—2017; Focus Theme: Allograft ischemic time". The Journal of Heart and Lung Transplantation. 36 (10): 1047–1059. doi:10.1016/j.healun.2017.07.016. ISSN 1053-2498.
- ↑ . doi:10.1016/j.healun.2017.07.019. Check
|doi=value (help). Missing or empty|title=(help) - ↑ Söderlund, Carl; Rådegran, Göran (2015). "Immunosuppressive therapies after heart transplantation — The balance between under- and over-immunosuppression". Transplantation Reviews. 29 (3): 181–189. doi:10.1016/j.trre.2015.02.005. ISSN 0955-470X.
- ↑ Herrero, María José; Megías, Juan Eduardo; Bosó, Virginia; Ruiz, Jesús; Rojas, Luis; Sánchez-Lázaro, Ignacio; Amenar, Luis; Hernández, Julio; Poveda, José Luis; Pastor, Amparo; Solé, Amparo; López-Andújar, Rafael; Aliño, Salvador F. (2016). "Pharmacogenetics of Immunosuppressants in Solid Organ Transplantation: Time to Implement in the Clinic". doi:10.5772/63071.
- ↑ Swinnen, Lode J.; Costanzo-Nordin, Maria R.; Fisher, Susan G.; O'Sullivan, E. Jeanne; Johnson, Maryl R.; Heroux, Alain L.; Dizikes, George J.; Pifarre, Roque; Fisher, Richard I. (1990). "Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients". New England Journal of Medicine. 323 (25): 1723–1728. doi:10.1056/NEJM199012203232502. ISSN 0028-4793.